Work

A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy

Year: 2020

Type: article

Abstract: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. Mechanisms of resistance to bevacizumab include increased VEGF signaling or activation of VEGF receptors. Pazopanib is a multi-targeted VEGF receptor tyrosine kinase with single agent activity in NSCLC.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/25tv-a649

Authors: Villaruz, Liza C., Weiss, Jared M., Grilley-Olson, Juneko, Ivanova, Anastasia, Stinchcombe, Thomas E., Dhruva, Nirav, Socinski, Mark A.

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4300667772

FWCI:

Cites:

Cited by:

Related to: 10